

			Phase 1	Phase 2	Phase 3
<b>Neurology</b>					
<b>valbenazine*</b>	Dyskinetic Cerebral Palsy	VMAT2 Inhibitor	[Progress bar: Phase 1 to Phase 3]		
<b>NBI-921352##</b>	Rare Pediatric Epilepsy: SCN8A-DEE	Na <sub>v</sub> 1.6	[Progress bar: Phase 1 to Phase 2]		
<b>NBI-1076986</b>	Movement Disorders	M4 Antagonist	[Progress bar: Phase 1]		
<b>Neuroendocrinology</b>					
<b>crinecerfont†</b>	Congenital Adrenal Hyperplasia in Adults	CRF <sub>1</sub>	[Progress bar: Phase 1 to Phase 3]		
<b>crinecerfont†</b>	Congenital Adrenal Hyperplasia in Children & Adolescents	CRF <sub>1</sub>	[Progress bar: Phase 1 to Phase 3]		
<b>modified-release hydrocortisone</b>	Adrenal Insufficiency	GC Receptor	[Progress bar: Phase 1 to Phase 2]		
<b>modified-release hydrocortisone</b>	Congenital Adrenal Hyperplasia	GC Receptor	[Progress bar: Phase 1 to Phase 2]		
<b>Neuropsychiatry</b>					
<b>valbenazine*</b>	Adjunctive Treatment of Schizophrenia	VMAT2 Inhibitor	[Progress bar: Phase 1 to Phase 3]		
<b>NBI-1065845¶</b>	Inadequate Response to Treatment in Major Depressive Disorder	AMPA	[Progress bar: Phase 1 to Phase 2]		
<b>NBI-1117568††</b>	Schizophrenia	M4 Agonist	[Progress bar: Phase 1 to Phase 2]		
<b>NBI-1070770¶</b>	Major Depressive Disorder	NMDA NR2B NAM	[Progress bar: Phase 1 to Phase 2]		
<b>NBI-1117570††</b>	CNS Indications	M1/M4 Agonist	[Progress bar: Phase 1]		
<b>NBI-1117569††</b>	CNS Indications	M4 Preferring Agonist	[Progress bar: Phase 1]		
<b>NBI-1117567††,**</b>	CNS Indications	M1 Preferring Agonist	[Progress bar: Phase 1]		
<b>NBI-1065890</b>	CNS Indications	VMAT2 Inhibitor	[Progress bar: Phase 1]		

SCN8A-DEE = SCN8A Developmental and Epileptic Encephalopathy Syndrome. Neurocrine Biosciences has global rights, unless otherwise noted. Neurocrine Biosciences shares profits and losses on NBI-1065845 with Takeda Pharmaceutical Company Limited.

\* Mitsubishi Tanabe Pharma Corporation has commercialization rights in Japan and other select Asian markets.  
## Licensed from Xenon Pharmaceuticals, Inc.  
† Licensed from Sanofi.

¶ Licensed from Takeda Pharmaceutical Company Limited.  
†† Licensed from Nxera Pharma (formerly Sosei Heptares).

\*\* Nxera Pharma (formerly Sosei Heptares) has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.